欧州がん光線力学療法市場規模、シェア、トレンド分析レポート – 業界概要と2032年までの予測

Customize Your Report レポートをカスタマイズする Buy Now 今すぐ購入 Free Sample Report 無料サンプルレポート
Home Healthcare Europe Cancer Photodynamic Therapy Market
Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Free Sample Report 無料サンプルレポート Inquire Before Buying 事前に問い合わせる Buy Now今すぐ購入

欧州がん光線力学療法市場規模、シェア、トレンド分析レポート – 業界概要と2032年までの予測

  • Healthcare
  • Published Report
  • Oct 2025
  • Europe
  • 350 ページ
  • テーブル数: 497
  • 図の数: 49
  • Author : Sachin Pawar
Buy Now 今すぐ購入 Request for Sample 無料サンプルPDFをダウンロード
Nucleus Nucleus

アジャイルなサプライチェーンコンサルティングで関税の課題を回避

サプライチェーンエコシステム分析は、現在DBMRレポートの一部です

欧州がん光線力学療法市場規模、シェア、トレンド分析レポート

Market Size in USD Billion

CAGR :  % Diagram

Chart Image USD 872.14 Million USD 1,353.25 Million 2024 2032
Diagram 予測期間
 2025 –2032
Diagram 市場規模（基準年）
 USD 872.14 Million
Diagram Market Size (Forecast Year)
 USD 1,353.25 Million
Diagram CAGR
 %
Diagram Major Markets Players
  • Novartis Pharma AG
  • Galderma SA
  • Bausch Health Companies Inc.
  • Photocure ASA
  • ADVANZ PHARMA Corp.

欧州がん光線力学療法市場セグメンテーション、製品タイプ別（光感受性薬、光線力学療法機器）、がん適応症別（皮膚・皮膚腫瘍、頭頸部、食道、肺、膀胱、子宮頸部、前立腺）、治療法別（単独療法、補助療法、緩和療法、その他）、治療技術別（体外照射、腔内（内視鏡）照射、組織内（内部）照射、その他）、病期別（早期がん、後期がん）、患者属性別（高齢者、成人、小児）、エンドユーザー別（病院、皮膚科・皮膚がんクリニック、外来手術センター（ASCS）、学術研究機関、その他）、流通チャネル別（直接入札、サードパーティ販売業者、オンライン、その他） - 業界動向と2025年までの予測2032

欧州がん光線力学療法市場

欧州がん光線力学療法市場規模

  • ヨーロッパのがん光線力学療法市場は2024年に8億7,214万米ドルと評価され、予測期間中に5.8%のCAGRで2032年までに13億5,325万米ドルに達すると予想されています。
  • 市場は主に、がん罹患率の上昇、医療費の増加、そして先進的な治療法への意識の高まりによって牽引されています。医療インフラの急速な改善、専門のがん治療センターの拡大などにより、
  • この成長は、早期診断と革新的な治療法を促進する政府の取り組み、大規模な患者プール、光線力学療法技術への国際企業と地元企業による投資の増加などの要因によって推進されています。

欧州がん光線力学療法市場分析

  • がん光線力学療法（PDT）市場は、がん罹患率の増加、非侵襲的治療への意識の高まり、光感受性薬やレーザー技術の進歩により、着実に成長しています。
  • 新興市場では、政府の取り組み、医療費の増加、そして高齢化人口の増加を背景に、PDTの導入が急速に進んでいます。しかし、治療費の高騰と限られた償還が依然として大きな制約となっています。一方で、併用療法や標的光感受性剤の継続的な革新は、大きな成長機会をもたらしています。
  • ドイツは、高度な医療インフラ、革新的な治療法の採用率の高さ、強力な研究開発投資、有利な償還政策、低侵襲療法の認知度に支えられ、2025年にはヨーロッパのがん光線力学療法市場で19.26%という最大の収益シェアを占めると予想されています。
  • ドイツは、がん罹患率の上昇、医療インフラの拡大、先進治療への意識の高まり、早期診断を促進する政府の取り組みを背景に、予測期間中に欧州がん光線力学療法市場において最も急速な成長を遂げる地域となり、年平均成長率（CAGR）は8.9%と予測されています。さらに、革新的技術の導入拡大と可処分所得の増加も、この地域における光線力学療法の需要を押し上げています。
  • 光増感剤セグメントは、治療における中心的な役割、がん細胞を標的とする高い特異性、新薬の承認の増加、併用療法の採用の増加、および有効性の向上と副作用の軽減を促進する継続的な研究開発により、2025年には75.15％の市場シェアでヨーロッパのがん光線力学療法市場を支配すると予想されています。

レポートの範囲と欧州がん光線力学療法市場のセグメンテーション 

属性

シルクキーマーケットインサイト

対象セグメント
  • 製品タイプ別:光感受性薬、光線力学療法装置
  • がんの適応症別：皮膚・皮膚腫瘍学、頭頸部、食道、肺、膀胱、子宮頸部、前立腺
  • 治療法別：単独療法、補助療法、緩和療法、その他
  • 手術法別：外照射、体腔内（内視鏡）照射、組織内（体内）照射、その他
  • 病気のステージ別：早期がん、末期がん
  • 患者属性別：高齢者、成人、小児
  • エンドユーザー別:病院、皮膚科・皮膚がんクリニック、外来手術センター（ASCS）、学術研究機関、その他
  • 流通チャネル別：直接入札、サードパーティ販売業者、オンライン、その他

対象国

 ヨーロッパ

  • ドイツ
  • 英国
  •  フランス
  •  イタリア
  •  スペイン
  •  ロシア
  •  七面鳥
  •  スイス
  •  ベルギー
  •  オランダ
  •  スウェーデン
  •  デンマーク
  •  ノルウェー
  •  フィンランド
  •  その他のヨーロッパ

主要な市場プレーヤー
  • ノバルティスファーマAG（スイス）
  • ガルデルマSA（スイス）
  • バウシュ・ヘルス・カンパニーズ社（カナダ）
  • Photocure ASA（ノルウェー）
  • ADVANZ PHARMA Corp.（英国）
  • サン・ファーマシューティカル・インダストリーズ（インド）
  • Biofrontera AG（ドイツ）
  • LUMIBIRD SA（フランス）
  • LUZITIN SA（ポルトガル）
  • ルメダ株式会社（スウェーデン）
  • ImPact Biotech（イスラエル）
  • biolitec Holding GmbH & Co KG（ドイツ）
  • モジュライトコーポレーション（フィンランド）
  • THERALASE TECHNOLOGIES INC.（カナダ）

市場機会
  • 他の癌治療との統合     
  • 新規光増感剤の開発

付加価値データ情報セット

データブリッジマーケットリサーチがまとめた市場レポートには、市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、輸出入分析、生産能力概要、生産消費分析、価格動向分析、気候変動シナリオ、サプライチェーン分析、バリューチェーン分析、原材料/消耗品概要、ベンダー選択基準、PESTLE分析、ポーター分析、規制枠組みも含まれています。

欧州がん光線力学療法市場動向

「他のがん治療との統合」

  • 光線力学療法（PDT）は、免疫反応を刺激しながら局所的な腫瘍細胞を死滅させる能力があり、マルチモーダル癌治療の魅力的なパートナーとして位置づけられています。
  • PDTは腫瘍抗原の放出を増加させ、腫瘍微小環境を調整し、免疫細胞の浸潤または活性化を促進できることがますます明らかになっています。これらのメカニズムは、免疫チェックポイント阻害剤、治療用癌ワクチン、化学療法、放射線療法と相乗効果を発揮する可能性があります。
  • PDTと全身療法を組み合わせることで、局所制御を持続的な全身反応に変換し、毒性物質の投与量を減らすことができ、適応症（切除不能または転移性疾患など）を拡大することができる。
  • 臨床研究とトランスレーショナルリサーチが増加するにつれて、他のモダリティとの統合はPDTの臨床的意義と商業的普及を拡大するための価値の高い道筋となる。

欧州がん光線力学療法市場の動向

ドライバ

「がんの罹患率の増加」

  • 世界的な癌罹患率の増加は、光線力学療法（PDT）などの治療法の需要を高める最大の要因の一つである。
  • 人口が増加し高齢化し、診断ツールが改良されるにつれて、毎年より多くの癌症例が検出されている。
  • 低所得国や中所得国では、喫煙、肥満、座りがちな生活、大気汚染、感染症などのリスク要因の割合が高いことも、発症率の上昇に寄与している。
  • 効果的で、侵襲性が低く、費用対効果の高い局所治療法を必要とする患者が増えるにつれて、PDTはより魅力的になります。
  • がんの負担の増加は医療システムに負担をかけ、治療成績を改善し、副作用を減らし、より広く展開できる治療法に対する緊急の圧力を生み出している。

抑制/挑戦

「光の浸透深度の制限」

  • 光線力学療法のより広範な採用と有効性を妨げる大きな制限は、活性化光の人体組織への浸透が制限されていることである。
  • 光感受性剤は特定の波長の光によって活性化される必要があるため、組織による光の吸収と散乱により、照射が到達できる深度が制限される。
  • 可視光PSは、表面またはアクセスしやすい腫瘍にのみ有効であることが多いが、より深いまたは大きな腫瘍では依然として困難である。
  • この制限により、腫瘍の破壊が不完全となり、侵襲的な光照射（例えば、ファイバープローブ、内視鏡検査）が必要となり、手順が複雑化し、予後不良や再発につながる可能性がある。
  • これを克服する画期的な進歩がない限り、PDTは非侵襲的かつ効果的に治療できる癌の範囲が制限されたままである。

欧州がん光線力学療法市場の範囲

市場は、製品タイプ、がんの適応症、治療法、処置技術、病気の段階、患者の人口統計、エンドユーザー、流通チャネルに基づいてセグメント化されています。

  • 製品タイプ別

製品タイプ別に見ると、欧州がん光線力学療法市場は、光感受性薬と光線力学療法機器に分類されます。2025年には、治療効果における重要な役割、幅広いがん種への適用性、そして多様な製剤（静脈内、局所、経口、膀胱内、腹腔内）により、光感受性薬が75.15%のシェアで市場を席巻すると予想されています。この市場シェア拡大の要因としては、がん罹患率の上昇、低侵襲療法の導入拡大、継続的な医薬品イノベーション、そして規制当局の承認などが挙げられ、これらが相まって光感受性薬はPDT機器を凌駕する主要な収益源となっています。

光増感剤（PDT）は、標的治療および低侵襲がん治療の普及拡大により、欧州がん光線力学療法市場において年平均成長率（CAGR）5.9%で最も急成長している分野です。PDTの有効性に対する認知度の高まり、従来の治療法に比べて副作用が少ないこと、そして腫瘍選択性が向上し組織深部への浸透性も向上した次世代光増感剤の開発が、需要を牽引しています。さらに、新規光増感剤の臨床研究と承認取得が市場拡大を後押ししています。

  • がんの兆候別

欧州がん光線力学療法市場は、がんの適応症に基づいて、皮膚・皮膚腫瘍、頭頸部、食道、肺、膀胱、子宮頸部、および前立腺に分類されています。2025年には、皮膚・皮膚腫瘍が52.21%のシェアを占め、市場を席巻すると予想されています。これは、皮膚がんの罹患率の高さ、早期発見への意識の高まり、そして優れた美容効果を実現するPDTの有効性によるものです。このセグメントは、特に最大の患者層である高齢者および成人患者において、光感受性薬とPDT機器の幅広い導入の恩恵を受けています。さらに、日光角化症、基底細胞がん、および扁平上皮がんに対する低侵襲性標的療法の需要の高まりと、主要地域における有利な償還ポリシーが、他のがん適応症に対する市場リーダーシップをさらに強化しています。

皮膚・皮膚腫瘍学分野は、欧州がん光線力学療法市場において、皮膚がんの罹患率の増加、早期診断への意識の高まり、そして副作用の少ない低侵襲治療への関心の高まりにより、6.3%のCAGRで成長しており、最も高い成長率を誇っています。光線力学療法は、標的への作用、迅速な回復、そして美容上の成果の向上を特徴としており、皮膚腫瘍学において非常に魅力的な治療法となっています。さらに、光感受性剤および光照射システムの技術進歩も、この分野における普及を促進しています。

  • 治療法別

治療様式に基づき、欧州がん光線力学療法市場は、独立療法、補助療法、緩和療法、その他に分類されます。2025年には、皮膚がん、食道がん、肺がんなどの局所がんの一次治療としての有効性から、独立療法セグメントが41.20%のシェアで市場を席巻すると予想されています。この優位性を推進する主な要因としては、高い有効性、低侵襲性、優れた美容効果、標的療法に対する臨床的選好の高まりなどが挙げられます。地域別では、北米と欧州が、高度な医療インフラ、確立された償還枠組み、高い患者認知度を背景に、独立型PDTの導入をリードしています。一方、アジア太平洋の新興市場では、がん罹患率の上昇、病院ネットワークの拡大、最新の腫瘍治療へのアクセス向上を背景に、導入が増加しています。こうした地域的な動向に加え、PDTの利点に関する教育と認知度の向上が、世界的に独立型PDTの優位性を強化しています。

欧州がん光線力学療法市場において、単独療法は6.2%のCAGR（年平均成長率）で最も急成長しているセグメントです。これは、併用療法に比べて簡便性、費用対効果、そして副作用の少なさによるものです。追加の薬剤や介入を必要とせずに腫瘍を標的とした治療が可能であるため、患者のコンプライアンスが向上します。外来診療における導入の増加、低侵襲治療への意識の高まり、そして光感受性剤と光照射システムの進歩が、このセグメントの急速な成長をさらに牽引しています。

  • 手順別テクニック

欧州がん光線力学療法市場は、手技別に、体外照射、体腔内（内視鏡的）照射、組織内（体内）照射、その他に分類されます。2025年には、体外照射セグメントが非侵襲性、使いやすさ、そして表在性腫瘍への有効性から、68.97%のシェアで市場を席巻すると予想されています。先進的な医療インフラと保険償還政策に支えられた北米および欧州での積極的な導入に加え、がんの罹患率と認知度の高まりに伴うアジア太平洋地域における需要の高まりが、このセグメントの市場リーダーシップを牽引しています。

腔内（内視鏡）送達セグメントは、中空臓器の腫瘍に対する最小限の侵襲性で標的を絞った光と光感受性剤の投与を可能にし、全身曝露と副作用を減らし、繰り返しの治療を可能にし、食道がん、気管支がん、膀胱がんにおける腫瘍へのアクセスを改善し、回復時間を短縮するため、ヨーロッパのがん光線力学療法市場において6.3%のCAGRで最も急速に成長しています。

  • 病気のステージ別

欧州におけるがん光線力学療法市場は、病期に基づいて、早期がんと後期がんに分類されます。2025年には、局所的な腫瘍へのPDTの有効性、健常組織へのダメージの最小化、そして美容上のメリットにより、早期がんセグメントが81.51%のシェアを占め、市場を席巻すると予想されています。このセグメントは、患者の高い認知度、低侵襲治療への嗜好、そして北米と欧州における広範な導入といった恩恵を受けています。また、アジア太平洋地域におけるがん診断率の上昇と腫瘍学インフラの拡大も、市場におけるPDTのリーダーシップを支えています。

早期がんは、欧州がん光線力学療法市場において、低侵襲治療の導入拡大、早期発見への意識の高まり、そしてPDTによる患者転帰の改善により、年平均成長率5.8%と最も急成長しているセグメントです。早期がんは標的療法への反応が良く、より高い有効性と少ない副作用をもたらします。さらに、政府の支援策や光感受性剤および光照射システムの進歩も、このセグメントの市場浸透を加速させています。

  • 患者の人口統計別

患者人口統計に基づき、欧州がん光線力学療法市場は、高齢者、成人、小児に分類されます。2025年には、高齢者のがん罹患率の高さ、皮膚がんおよび皮膚癌に対する感受性の高まり、そして低侵襲性で標的を絞った治療への嗜好により、高齢者セグメントが67.12%のシェアを占め、市場を席巻すると予想されています。北米と欧州では、先進的な医療インフラと意識、そして高齢者人口の増加に支えられ、光線力学療法の導入が進んでいます。

欧州がん光線力学療法市場において、高齢者セグメントは6.0%のCAGR（年平均成長率）で最も高い成長率を示しています。これは、高齢者のがん罹患率が高いことが要因です。加齢に伴い免疫系が弱まり、様々ながんに対する感受性が高まるため、PDTのような効果的で低侵襲な治療への需要が高まっています。さらに、PDTは副作用が少なく回復が早いため、積極的な治療に耐えられない高齢患者にも適しており、この年齢層における市場成長を牽引しています。

  • エンドユーザー別

エンドユーザーに基づいて、欧州がん光線力学療法市場は、病院、皮膚科・皮膚がんクリニック、外来手術センター（ASCS）、学術研究機関、その他に分類されます。2025年には、包括的なインフラ、専門の腫瘍科の存在、そして統合PDT治療の提供能力により、病院セグメントが41.33%のシェアで市場を席巻すると予想されています。北米と欧州の公立・私立病院、特にティア1およびティア2の施設は、高度な医療システムと償還サポートにより、PDTの導入をリードしています。アジア太平洋地域における病院ネットワークの拡大と腫瘍学サービスの拡大は、世界的にがんPDTの主要エンドユーザーとしての病院の優位性をさらに強化しています。

欧州がん光線力学療法市場において、病院は6.5%の年平均成長率（CAGR）で最速の成長セグメントです。これは、高度ながん治療の導入、患者流入の増加、そして専門の腫瘍科の存在によるものです。病院は診断、治療、そして治療後のケアを含む包括的なPDTサービスを提供しているため、独立したクリニックよりも好まれています。さらに、意識の高まり、政府の取り組み、そして保険適用範囲の拡大も、病院におけるPDTの導入をさらに促進しています。

  • 流通チャネル別

流通チャネルに基づいて、欧州がん光線力学療法市場は、直接入札、第三者販売代理店、オンライン、その他に分類されます。2025年には、病院、政府の医療プログラム、大規模な腫瘍センターによる一括調達により、光感受性剤およびPDT機器のコスト効率と安定供給が確保されるため、直接入札セグメントが50.79%のシェアで市場を席巻すると予想されます。北米と欧州では、構造化された病院調達システムと公衆衛生入札、そして機関からの需要の増加に支えられ、導入が進んでいます。

欧州がん光線力学療法市場において、直接入札セグメントは6.0%のCAGR（年平均成長率）で最も高い成長率を示しています。これは、政府や病院による高度なPDT機器の直接契約による調達の増加によるものです。このアプローチは、大規模ながん治療プログラムにおいて、費用対効果の高い調達、迅速な調達、そして安定した供給を確保します。さらに、公的医療費の増加、がん治療に対する政府の取り組み、そして集中購買への志向が、販売代理店やオンラインチャネルよりも直接入札の採用を促進しています。

欧州がん光線力学療法市場地域分析

  • ドイツは、高度な医療インフラ、革新的な治療法の採用率の高さ、強力な研究開発投資、有利な償還政策、低侵襲療法の認知度に支えられ、2025年にはヨーロッパのがん光線力学療法市場で19.26%という最大の収益シェアを占めると予想されています。
  • ドイツは、がん罹患率の上昇、医療インフラの拡大、先進治療への意識の高まり、早期診断を促進する政府の取り組みを背景に、予測期間中に欧州がん光線力学療法市場において最も急速な成長を遂げる地域となり、年平均成長率（CAGR）は8.9%と予測されています。さらに、革新的技術の導入拡大と可処分所得の増加も、この地域における光線力学療法の需要を押し上げています。
  • さらに、主要な市場プレーヤーと支援的な規制枠組みの存在により、この地域の市場成長と導入率が加速しています。

英国・欧州におけるがん光線力学療法市場の洞察

英国・欧州におけるがん光線力学療法（PDT）市場は、強力な医療インフラ、高度な研究能力、そして確立された腫瘍学センターを背景に、欧州の医療用プラスチック業界において重要な役割を果たしています。革新的な治療法の普及率の高さ、がん治療に対する政府の強力な支援、そして活発な臨床試験が市場の成長を牽引しています。さらに、英国では製薬会社と研究機関の連携がPDTの開発と商業化を加速させており、PDTは欧州市場への重要な貢献者となっています。

ドイツ・ヨーロッパにおけるがん光線力学療法市場の洞察

ドイツ・ヨーロッパにおけるがん光線力学療法市場は、高度な医療インフラ、革新的ながん治療の普及率の高さ、そしてがん研究に対する政府の強力な支援に支えられ、着実に成長すると予測されています。低侵襲療法への認知度の高まり、皮膚がんや肺がんなどの発症率の上昇、そして新規治療法に対する保険償還政策が、その普及をさらに後押ししています。さらに、主要なPDT機器メーカーの存在と研究協力が、市場浸透と持続的な成長を加速させています。

市場で活動する主要なマーケットリーダーは次のとおりです。

  • ノバルティスファーマAG（スイス）
  • ガルデルマSA（スイス）
  • バウシュ・ヘルス・カンパニーズ（カナダ）
  • Photocure ASA（ノルウェー）
  • アドバンツ・ファーマ社（英国）
  • サン・ファーマシューティカル・インダストリーズ（インド）
  • Biofrontera AG（ドイツ）
  • LUMIBIRD SA（フランス）
  • LUZITIN SA（ポルトガル）
  • ルメダ株式会社（スウェーデン）
  • ImPact Biotech（イスラエル）
  • biolitec Holding GmbH & Co KG（ドイツ）
  • モジュライトコーポレーション（フィンランド）
  • THERALASE TECHNOLOGIES INC.（カナダ）

欧州がん光線力学療法市場の最新動向

  • 2023年2月、ガルデルマ社とGerman Medical Engineering（GME）は、皮膚科および光線力学療法（PDT）市場における戦略的展開を象徴する提携を開始しました。前癌性および非黒色腫皮膚がんに対する優れた光感受性剤であるガルデルマ社のMetvixとGME社のMultiLiteデバイスを組み合わせることで、この提携はガルデルマの統合治療製品ラインナップを強化し、従来の赤色光PDT（C-PDT）と、より患者様への負担が少ない人工昼光PDT（ADL-PDT）の両方を提供する能力を拡大します。
  • 2025年、マッケソンはCore Ventures（コミュニティ腫瘍学再活性化エンタープライズベンチャー）の買収を完了し、約24億9000万米ドルで約70％の支配権を取得し、フロリダがん専門医＆研究機関を通じてコミュニティベースの腫瘍学ケアを強化しました。
  • 2025年、Biofrontera AGはAmeluzおよびRhodoLEDに関連するすべての米国資産をBiofrontera Inc.に譲渡し、10%の株式と米国でのAmeluzの売上の12～15%のロイヤルティを受け取りました。

SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

Sample Image 画像をクリックすると拡大します
  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE CANCER PHOTODYNAMIC THERAPY MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 PRODUCTION CONSUMPTION ANALYSIS

4.3.1 INTRODUCTION

4.3.2 PRODUCTION SIDE ANALYSIS

4.3.2.1 PHOTOSENSITIZER MANUFACTURING

4.3.2.2 DEVICE MANUFACTURING

4.3.2.3 RESEARCH AND INNOVATION

4.3.3 CONSUMPTION SIDE ANALYSIS

4.3.3.1 CLINICAL APPLICATION

4.3.3.2 TREATMENT VOLUMES AND TRENDS

4.3.3.3 DOSAGE AND PROTOCOLS

4.3.4 PRODUCTION–CONSUMPTION DYNAMICS

4.3.4.1 SUPPLY CONSTRAINTS

4.3.4.2 REGIONAL OVERVIEW

4.3.4.3 FUTURE OUTLOOK

4.3.5 CONCLUSION

4.4 COST ANALYSIS BREAKDOWN

4.4.1 INTRODUCTION

4.4.2 DIRECT MEDICAL COSTS

4.4.2.1 COST OF PHOTOSENSITIZERS

4.4.2.2 LIGHT DELIVERY SYSTEMS

4.4.2.3 HEALTHCARE FACILITY CHARGES

4.4.3 INDIRECT COSTS

4.4.3.1 PATIENT-RELATED EXPENSES

4.4.3.2 POST-TREATMENT MONITORING

4.4.4 COMPARATIVE COST-EFFECTIVENESS

4.4.5 REIMBURSEMENT AND INSURANCE IMPACT

4.4.6 REGIONAL COST VARIATIONS

4.4.7 FUTURE COST TRENDS AND REDUCTION STRATEGIES

4.4.7.1 TECHNOLOGICAL ADVANCEMENTS

4.4.7.2 HEALTHCARE EFFICIENCY INITIATIVES

4.4.8 CONCLUSION

4.5 TECHNOLOGICAL ADVANCEMENTS

4.5.1 INTRODUCTION

4.5.2 NEXT-GENERATION PHOTOSENSITIZERS

4.5.3 ADVANCEMENTS IN LIGHT DELIVERY SYSTEMS

4.5.4 NANOTECHNOLOGY-ENABLED DELIVERY

4.5.5 COMBINATION THERAPIES AND IMMUNOMODULATION

4.5.6 DIGITAL INTEGRATION AND TREATMENT PLANNING

4.5.7 RECENT TRENDS AND OUTLOOK

4.5.8 CONCLUSION

4.6 VALUE CHAIN ANALYSIS

4.6.1 INTRODUCTION

4.6.2 RESEARCH & DEVELOPMENT

4.6.2.1 DISCOVERY OF PHOTOSENSITIZERS

4.6.2.2 DEVELOPMENT OF LIGHT DELIVERY SYSTEMS

4.6.2.3 CLINICAL TRIALS AND REGULATORY APPROVALS

4.6.3 MANUFACTURING

4.6.3.1 PRODUCTION OF PHOTOSENSITIZERS

4.6.3.2 FABRICATION OF LIGHT DELIVERY DEVICES

4.6.4 DISTRIBUTION & LOGISTICS

4.6.4.1 SUPPLY CHAIN MANAGEMENT

4.6.4.2 INTERNATIONAL TRADE AND MARKET ACCESS

4.6.5 CLINICAL APPLICATION

4.6.5.1 INTEGRATION INTO TREATMENT PROTOCOLS

4.6.5.2 TRAINING AND EDUCATION

4.6.6 POST-TREATMENT MONITORING & SUPPORT

4.6.6.1 FOLLOW-UP CARE

4.6.6.2 PATIENT SUPPORT SERVICES

4.6.7 TECHNOLOGICAL ADVANCEMENTS INFLUENCING THE PDT VALUE CHAIN

4.6.7.1 NANOTECHNOLOGY IN PDT

4.6.7.2 ARTIFICIAL INTELLIGENCE AND IMAGING

4.6.7.3 PERSONALIZED MEDICINE

4.6.8 CONCLUSION

4.7 VENDOR SELECTION CRITERIA

4.7.1 INTRODUCTION

4.7.2 CORE SELECTION CRITERIA

4.7.2.1 REGULATORY COMPLIANCE

4.7.2.2 CLINICAL EVIDENCE AND RESEARCH SUPPORT

4.7.2.3 TECHNICAL PERFORMANCE AND DEVICE COMPATIBILITY

4.7.2.4 QUALITY MANAGEMENT AND MANUFACTURING STANDARDS

4.7.2.5 SERVICE, TRAINING, AND AFTER-SALES SUPPORT

4.7.2.6 SUPPLY CHAIN RELIABILITY

4.7.3 RECENT TRENDS IN VENDOR SELECTION

4.7.4 RISK FACTORS AND VULNERABILITIES

4.7.5 KEY PERFORMANCE INDICATORS

4.7.6 STRATEGIC RECOMMENDATIONS

4.7.7 CONCLUSION

4.8 PATENT ANALYSIS

4.8.1 PATENT QUALITY AND STRENGTH

4.8.2 PATENT FAMILIES

4.8.3 LICENSING AND COLLABORATIONS

4.8.4 REGIONAL PATENT LANDSCAPE

4.8.5 IP STRATEGY AND MANAGEMENT

4.9 SUPPLY CHAIN ANALYSIS

4.9.1 OVERVIEW

4.9.2 LOGISTIC COST SCENARIO

4.9.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS

4.9.4 CONCLUSION

4.1 INDUSTRY ECOSYSTEM ANALYSIS

4.10.1 INTRODUCTION

4.10.2 ECOSYSTEM ARCHITECTURE — KEY ACTORS AND ROLES

4.10.2.1 CORE TECHNOLOGY PROVIDERS

4.10.2.2 ENABLING INSTITUTIONS

4.10.3 VALUE CHAIN AND FUNCTIONAL FLOWS

4.10.3.1 RESEARCH AND DISCOVERY

4.10.3.2 CLINICAL DEVELOPMENT AND REGULATORY VALIDATION

4.10.3.3 MANUFACTURING AND QUALITY ASSURANCE

4.10.3.4 DISTRIBUTION, PROCUREMENT AND CLINICAL ADOPTION

4.10.4 MARKET ENABLERS AND INFRASTRUCTURE

4.10.4.1 SCIENTIFIC AND REGULATORY ENABLERS

4.10.4.2 REIMBURSEMENT AND HEALTH-ECONOMICS INFRASTRUCTURE

4.10.4.3 MANUFACTURING AND SUPPLY-CHAIN CAPACITY

4.10.5 INTERDEPENDENCIES AND STRATEGIC PARTNERSHIPS

4.10.5.1 ACADEMIA-INDUSTRY TECHNOLOGY TRANSFER

4.10.5.2 VERTICAL INTEGRATION AND CONTRACT MANUFACTURING

4.10.5.3 CLINICAL NETWORKS AND KOL ECOSYSTEMS

4.10.6 RISKS, CONSTRAINTS AND SYSTEMIC VULNERABILITIES

4.10.6.1 REGULATORY COMPLEXITY FOR COMBINED PRODUCTS

4.10.6.2 SUPPLY-CHAIN CONCENTRATION AND MATERIAL RISK

4.10.6.3 EVIDENCE AND REIMBURSEMENT UNCERTAINTY

4.10.6.4 CLINICAL OPERATIONAL BARRIERS

4.10.7 STRATEGIC IMPLICATIONS AND RECOMMENDATIONS

4.10.8 OUTLOOK — EVOLUTION OF THE ECOSYSTEM

4.10.9 CONCLUSION

4.11 INNOVATION TRACKER AND STRATEGIC ANALYSIS

4.11.1 INTRODUCTION

4.11.2 RECENT TECHNOLOGICAL INNOVATIONS

4.11.2.1 ADVANCED PHOTOSENSITIZERS

4.11.2.2 OXYGEN-SELF-SUFFICIENT PLATFORMS

4.11.2.3 ALTERNATIVE ACTIVATION MODALITIES

4.11.2.4 SMART NANOPLATFORMS

4.11.2.5 NOVEL CHEMICAL STRUCTURES

4.11.3 STRATEGIC INNOVATIONS IN DELIVERY SYSTEMS

4.11.3.1 LIGHT DELIVERY DEVICES

4.11.3.2 COMBINATION THERAPIES

4.11.3.3 IMAGING INTEGRATION

4.11.4 KEY CHALLENGES

4.11.5 STRATEGIC THEMES

4.11.6 STRATEGIC IMPLICATIONS FOR MARKET PLAYERS

4.11.7 RECOMMENDATIONS

4.11.8 OUTLOOK AND STRATEGIC RISKS

4.11.9 CONCLUSION

4.12 PRICING ANALYSIS

4.12.1 INTRODUCTION

4.12.2 COMPONENTS OF THE TOTAL TREATMENT PRICE

4.12.2.1 PHOTOSENSITIZING AGENT (DRUG) COSTS

4.12.2.2 DEVICE CAPITAL AND MAINTENANCE COST

4.12.2.3 CONSUMABLES AND PROCEDURAL OVERHEAD

4.12.2.4 INDIRECT AND DOWNSTREAM COSTS

4.12.3 PRICING MODELS AND APPROACHES

4.12.3.1 COST-PLUS AND MARKUP MODELS

4.12.3.2 VALUE-BASED AND OUTCOMES-LINKED PRICING

4.12.3.3 BUNDLED PAYMENTS AND PROCEDURAL TARIFFS

4.12.3.4 SUBSCRIPTION AND MANAGED-SERVICE MODELS FOR DEVICES

4.12.4 REIMBURSEMENT LANDSCAPE

4.12.4.1 UNITED STATES: MEDICARE AND COMMERCIAL PAYERS

4.12.4.2 EUROPE AND OTHER HIGH-INCOME MARKETS

4.12.4.3 EMERGING MARKETS AND OUT-OF-POCKET DYNAMICS

4.12.5 REGIONAL PRICE DIFFERENTIALS AND DRIVERS

4.12.5.1 MANUFACTURING FOOTPRINT AND SUPPLY-CHAIN EFFECTS

4.12.5.2 REGULATORY BURDEN AND MARKET ACCESS TIMELINES

4.12.5.3 CLINICAL PRACTICE PATTERNS AND REIMBURSEMENT POLICY

4.12.6 PRICE SENSITIVITY, ACCESS, AND EQUITY

4.12.6.1 PRICE ELASTICITY IN HOSPITAL PROCUREMENT

4.12.6.2 PATIENT ACCESS AND SOCIOECONOMIC BARRIERS

4.12.7 COMPETITIVE & STRATEGIC PRICING IMPLICATIONS

4.12.7.1 DIFFERENTIATION-BASED PREMIUM PRICING

4.12.7.2 PENETRATION PRICING AND VOLUME STRATEGIES

4.12.7.3 MANAGED ENTRY AGREEMENTS AND OUTCOMES GUARANTEES

4.12.8 RECOMMENDATIONS FOR STAKEHOLDERS

4.12.8.1 FOR MANUFACTURERS

4.12.8.2 FOR PROVIDERS AND HOSPITAL SYSTEMS

4.12.8.3 FOR PAYERS AND POLICYMAKERS

4.12.9 RISKS, UNCERTAINTIES, AND FUTURE PRICE PRESSURES

4.12.10 CONCLUSION

5 TARIFFS & IMPACT ON THE MARKET

5.1 INTRODUCTION

5.2 TARIFF LANDSCAPE RELEVANT TO PDT PRODUCTS

5.2.1 CATEGORIES OF TRADE EXPOSURE

5.2.2 RECENT AND EMERGING TARIFF MEASURES OF CONSEQUENCE

5.3 DIRECT COST IMPACTS

5.3.1 INCREASED LANDED COSTS AND MARGIN COMPRESSION

5.3.2 PRICE VOLATILITY AND PROCUREMENT BUDGETING

5.4 SUPPLY-CHAIN & MANUFACTURING IMPLICATIONS

5.4.1 SUPPLIER DIVERSIFICATION AND RESHORING INCENTIVES

5.4.2 SOURCING OF HIGH-VALUE NANOMATERIALS AND COMPONENTS

5.4.3 REGULATORY AND QUALIFICATION COSTS FOR NEW SUPPLIERS

5.5 CLINICAL ACCESS, PRICING & REIMBURSEMENT EFFECTS

5.5.1 ACCESS RISK FOR PATIENTS AND PROVIDERS

5.5.2 REIMBURSEMENT PRESSURE AND HEALTH-ECONOMIC ASSESSMENTS

5.6 R&D, INNOVATION & COMPETITIVE IMPLICATIONS

5.6.1 DISRUPTION OF RESEARCH SUPPLIES AND COLLABORATION FLOWS

5.6.2 STRATEGIC REPOSITIONING AND COMPETITIVE ADVANTAGE

5.7 POLICY, COMPLIANCE & REGULATORY CONSIDERATIONS

5.7.1 USE OF WTO AND PREFERENTIAL TRADE RULES

5.7.2 TARIFF MITIGATION TOOLS AND ADVOCACY

5.8 RECOMMENDATIONS FOR STAKEHOLDERS

5.9 CONCLUSION

6 REGULATION COVERAGE

6.1 PRODUCT CODES

6.1.1 CERTIFIED STANDARDS

6.1.2 SAFETY STANDARDS

6.1.3 MATERIAL HANDLING & STORAGE

6.1.4 TRANSPORT & PRECAUTIONS

6.1.5 HAZARD IDENTIFICATION

6.1.6 CONCLUSION

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF CANCER

7.1.2 GROWING PREFERENCE FOR MINIMALLY INVASIVE THERAPIES

7.1.3 TECHNOLOGICAL ADVANCEMENTS IN PHOTOSENSITIZERS AND DEVICES

7.1.4 EXPANDING RESEARCH AND CLINICAL DEVELOPMENT PIPELINE

7.2 RESTRAINTS

7.2.1 LIMITED DEPTH OF LIGHT PENETRATION

7.2.2 HIGH COST OF TREATMENT

7.3 OPPORTUNITIES

7.3.1 INTEGRATION WITH OTHER CANCER THERAPIES

7.3.2 DEVELOPMENT OF NOVEL PHOTOSENSITIZERS

7.3.3 M&A AND PARTNERSHIPS WITH ONCOLOGY DEVICE/LASER FIRMS AND PHARMA

7.4 CHALLENGES

7.4.1 TUMOR HYPOXIA AS A BIOLOGICAL BARRIER TO PHOTODYNAMIC THERAPY EFFICACY

7.4.2 COMPETITION FROM ALTERNATIVE TREATMENTS

8 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 PHOTOSENSITIZER DRUGS

8.3 PHOTODYNAMIC THERAPY DEVICES

9 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION

9.1 OVERVIEW

9.2 SKIN & CUTANEOUS ONCOLOGY

9.3 HEAD & NECK

9.4 ESOPHAGAL

9.5 LUNG

9.6 BLADDER

9.7 CERVICAL

9.8 PROSTATE

10 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY

10.1 OVERVIEW

10.2 STANDALONE THERAPY

10.3 ADJUNCTIVE THERAPY

10.4 PALLIATION THERAPY

10.5 OTHERS

11 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE

11.1 OVERVIEW

11.2 EXTERNAL BEAM

11.3 INTRACAVITARY (ENDOSCOPIC) DELIVERY

11.4 INTERSTITIAL (INTERNAL) DELIVERY

11.5 OTHERS

12 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE

12.1 OVERVIEW

12.2 EARLY-STAGE CANCER

12.3 LATE-STAGE CANCER

13 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS

13.1 OVERVIEW

13.2 GERIATRIC

13.3 ADULTS

13.4 PEDIATRIC

14 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 DERMATOLOGY & SKIN-CANCER CLINICS

14.4 AMBULATORY SURGICAL CENTERS (ASCS)

14.5 ACADEMIC & RESEARCH INSTITUTES

14.6 OTHERS

15 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 THIRD PARTY DISTRIBUTORS

15.4 ONLINE

15.5 OTHERS

16 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION

16.1 EUROPE

16.1.1 GERMANY

16.1.2 U.K.

16.1.3 FRANCE

16.1.4 ITALY

16.1.5 SPAIN

16.1.6 RUSSIA

16.1.7 TURKEY

16.1.8 SWITZERLAND

16.1.9 BELGIUM

16.1.10 NETHERLANDS

16.1.11 SWEDEN

16.1.12 DENMARK

16.1.13 NORWAY

16.1.14 FINLAND

16.1.15 REST OF EUROPE

17 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 NOVERTIS AG

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 GALDERMA S. A.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 PHOTOCURE

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 ADVANZ PHARMA CORP.

19.4.1 COMPANY SNAPSHOT

19.4.2 COMPANY SHARE ANALYSIS

19.4.3 PRODUCT PORTFOLIO

19.4.4 RECENT DEVELOPMENT

19.5 AMERISOURCE BERGEN CORPORATION

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 BIOFRONTERA AG

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENTS

19.7 BIOLITEC HOLDING GMBH & CO KG

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 CARDINAL HEALTH

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENT

19.9 HEMERION THERAPEUTICS

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENTS

19.1 IMPACT BIOTECH

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENTS

19.11 INOVA

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENT

19.12 LUMIBIRD

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 LUZITIN

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 MCKESSON

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENTS

19.15 MODULIGHT CORPORATION

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 ONCOLUX INC (FORMERLY LUMEDA INC.)

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 SUN PHARMACEUTICAL INDUSTRIES LTD

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENT

19.18 THERALASE TECHNOLOGIES INC.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

表のリスト

TABLE 1 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 2 EUROPE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 3 EUROPE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 4 EUROPE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 5 EUROPE PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 6 EUROPE PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 7 EUROPE LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 EUROPE ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 9 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 10 EUROPE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 11 EUROPE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 12 EUROPE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 13 EUROPE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 14 EUROPE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 15 EUROPE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 16 EUROPE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 17 EUROPE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 EUROPE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 19 EUROPE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 20 EUROPE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 EUROPE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 22 EUROPE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 23 EUROPE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 24 EUROPE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 25 EUROPE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 26 EUROPE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 27 EUROPE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 28 EUROPE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 29 EUROPE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 EUROPE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 31 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 32 EUROPE STANDALONE THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 33 EUROPE ADJUNCTIVE THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 34 EUROPE PALLIATION THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 35 EUROPE OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 36 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 37 EUROPE EXTERNAL BEAM IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 38 EUROPE INTRACAVITARY (ENDOSCOPIC) DELIVERY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 39 EUROPE INTERSTITIAL (INTERNAL) DELIVERY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 40 EUROPE OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 41 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 42 EUROPE EARLY-STAGE CANCER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 43 EUROPE LATE-STAGE CANCER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 44 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 45 EUROPE GERIATRIC IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 46 EUROPE ADULTS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 47 EUROPE PEDIATRIC IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 48 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 49 EUROPE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 50 EUROPE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 EUROPE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 52 EUROPE DERMATOLOGY & SKIN-CANCER CLINICS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 EUROPE AMBULATORY SURGICAL CENTERS (ASCS) IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 54 EUROPE ACADEMIC & RESEARCH INSTITUTES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 55 EUROPE OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 56 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 57 EUROPE DIRECT TENDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 58 EUROPE THIRD PARTY DISTRIBUTORS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 59 EUROPE ONLINE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 60 EUROPE OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 61 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 62 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 EUROPE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 64 EUROPE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 65 EUROPE PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 66 EUROPE LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 EUROPE ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 69 EUROPE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 70 EUROPE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 71 EUROPE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 72 EUROPE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 73 EUROPE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 74 EUROPE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 75 EUROPE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 EUROPE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 77 EUROPE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 78 EUROPE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 79 EUROPE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 80 EUROPE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 81 EUROPE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 EUROPE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 83 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 84 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 85 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 86 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 87 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 88 EUROPE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 89 EUROPE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 90 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 91 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 92 GERMANY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 93 GERMANY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 94 GERMANY PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 95 GERMANY LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 GERMANY ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 97 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 98 GERMANY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 99 GERMANY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 100 GERMANY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 101 GERMANY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 102 GERMANY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 103 GERMANY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 104 GERMANY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 105 GERMANY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 106 GERMANY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 107 GERMANY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 108 GERMANY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 GERMANY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 110 GERMANY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 GERMANY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 112 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 113 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 114 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 115 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 116 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 117 GERMANY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 118 GERMANY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 119 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 120 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 121 U.K. PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 122 U.K. PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 123 U.K. PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 124 U.K. LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 U.K. ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 127 U.K. SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 U.K. SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 129 U.K. HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 130 U.K. HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 131 U.K. ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 U.K. ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 133 U.K. LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 134 U.K. LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 135 U.K. BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 136 U.K. BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 137 U.K. CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 138 U.K. CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 139 U.K. PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 U.K. PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 141 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 142 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 143 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 144 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 145 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 146 U.K. HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 147 U.K. HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 148 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 149 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 FRANCE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 151 FRANCE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 152 FRANCE PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 FRANCE LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 FRANCE ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 156 FRANCE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 FRANCE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 158 FRANCE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 FRANCE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 160 FRANCE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 FRANCE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 162 FRANCE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 FRANCE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 164 FRANCE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 FRANCE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 166 FRANCE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 FRANCE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 168 FRANCE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 FRANCE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 170 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 171 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 172 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 173 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 174 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 175 FRANCE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 FRANCE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 177 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 178 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 ITALY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 180 ITALY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 181 ITALY PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 ITALY LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 183 ITALY ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 184 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 185 ITALY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 186 ITALY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 187 ITALY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 ITALY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 189 ITALY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 ITALY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 191 ITALY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 192 ITALY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 193 ITALY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 ITALY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 195 ITALY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 ITALY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 197 ITALY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 ITALY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 199 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 200 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 201 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 202 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 203 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 204 ITALY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 ITALY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 206 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 207 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 SPAIN PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 209 SPAIN PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 210 SPAIN PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 SPAIN LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 SPAIN ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 213 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 214 SPAIN SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 SPAIN SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 216 SPAIN HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 SPAIN HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 218 SPAIN ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 SPAIN ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 220 SPAIN LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 SPAIN LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 222 SPAIN BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 SPAIN BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 224 SPAIN CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 SPAIN CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 226 SPAIN PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 SPAIN PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 228 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 229 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 230 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 231 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 232 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 233 SPAIN HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 234 SPAIN HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 235 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 236 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 RUSSIA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 238 RUSSIA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 239 RUSSIA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 240 RUSSIA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 241 RUSSIA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 242 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 243 RUSSIA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 244 RUSSIA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 245 RUSSIA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 RUSSIA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 247 RUSSIA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 248 RUSSIA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 249 RUSSIA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 RUSSIA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 251 RUSSIA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 RUSSIA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 253 RUSSIA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 RUSSIA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 255 RUSSIA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 RUSSIA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 257 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 258 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 259 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 260 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 261 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 262 RUSSIA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 263 RUSSIA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 264 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 265 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 TURKEY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 267 TURKEY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 268 TURKEY PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 TURKEY LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 TURKEY ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 271 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 272 TURKEY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 TURKEY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 274 TURKEY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 TURKEY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 276 TURKEY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 TURKEY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 278 TURKEY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 TURKEY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 280 TURKEY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 281 TURKEY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 282 TURKEY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 TURKEY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 284 TURKEY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 TURKEY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 286 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 287 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 288 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 289 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 290 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 291 TURKEY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 292 TURKEY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 293 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 294 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 295 SWITZERLAND PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 296 SWITZERLAND PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 297 SWITZERLAND PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 SWITZERLAND LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 SWITZERLAND ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 301 SWITZERLAND SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 SWITZERLAND SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 303 SWITZERLAND HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 SWITZERLAND HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 305 SWITZERLAND ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 SWITZERLAND ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 307 SWITZERLAND LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 SWITZERLAND LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 309 SWITZERLAND BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 SWITZERLAND BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 311 SWITZERLAND CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 SWITZERLAND CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 313 SWITZERLAND PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 314 SWITZERLAND PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 315 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 316 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 317 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 318 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 319 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 320 SWITZERLAND HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 321 SWITZERLAND HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 322 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 323 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 BELGIUM PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 325 BELGIUM PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 326 BELGIUM PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 BELGIUM LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 328 BELGIUM ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 330 BELGIUM SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 BELGIUM SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 332 BELGIUM HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 333 BELGIUM HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 334 BELGIUM ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 BELGIUM ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 336 BELGIUM LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 BELGIUM LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 338 BELGIUM BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 339 BELGIUM BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 340 BELGIUM CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 341 BELGIUM CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 342 BELGIUM PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 BELGIUM PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 344 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 345 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 346 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 347 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 348 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 349 BELGIUM HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 BELGIUM HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 351 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 352 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 353 NETHERLANDS PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 354 NETHERLANDS PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 355 NETHERLANDS PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 NETHERLANDS LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 NETHERLANDS ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 359 NETHERLANDS SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 NETHERLANDS SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 361 NETHERLANDS HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 NETHERLANDS HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 363 NETHERLANDS ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 364 NETHERLANDS ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 365 NETHERLANDS LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 NETHERLANDS LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 367 NETHERLANDS BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 368 NETHERLANDS BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 369 NETHERLANDS CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 NETHERLANDS CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 371 NETHERLANDS PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 NETHERLANDS PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 373 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 374 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 375 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 376 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 377 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 378 NETHERLANDS HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 NETHERLANDS HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 380 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 381 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 SWEDEN PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 383 SWEDEN PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 384 SWEDEN PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 SWEDEN LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 386 SWEDEN ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 388 SWEDEN SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 389 SWEDEN SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 390 SWEDEN HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 391 SWEDEN HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 392 SWEDEN ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 SWEDEN ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 394 SWEDEN LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 395 SWEDEN LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 396 SWEDEN BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 397 SWEDEN BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 398 SWEDEN CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 399 SWEDEN CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 400 SWEDEN PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 SWEDEN PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 402 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 403 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 404 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 405 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 406 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 407 SWEDEN HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 SWEDEN HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 409 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 410 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 DENMARK PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 412 DENMARK PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 413 DENMARK PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 414 DENMARK LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 DENMARK ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 417 DENMARK SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 418 DENMARK SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 419 DENMARK HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 420 DENMARK HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 421 DENMARK ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 DENMARK ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 423 DENMARK LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 424 DENMARK LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 425 DENMARK BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 DENMARK BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 427 DENMARK CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 428 DENMARK CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 429 DENMARK PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 430 DENMARK PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 431 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 432 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 433 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 434 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 435 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 436 DENMARK HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 DENMARK HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 438 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 439 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 NORWAY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 441 NORWAY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 442 NORWAY PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 NORWAY LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 444 NORWAY ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 445 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 446 NORWAY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 447 NORWAY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 448 NORWAY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 449 NORWAY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 450 NORWAY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 NORWAY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 452 NORWAY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 453 NORWAY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 454 NORWAY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 455 NORWAY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 456 NORWAY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 NORWAY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 458 NORWAY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 459 NORWAY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 460 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 461 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 462 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 463 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 464 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 465 NORWAY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 466 NORWAY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 467 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 468 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 469 FINLAND PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 470 FINLAND PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 471 FINLAND PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 472 FINLAND LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 473 FINLAND ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 474 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 475 FINLAND SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 476 FINLAND SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 477 FINLAND HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 478 FINLAND HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 479 FINLAND ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 480 FINLAND ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 481 FINLAND LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 482 FINLAND LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 483 FINLAND BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 484 FINLAND BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 485 FINLAND CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 486 FINLAND CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 487 FINLAND PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 488 FINLAND PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 489 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 490 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 491 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 492 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 493 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 494 FINLAND HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 495 FINLAND HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 496 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 497 REST OF EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

図表一覧

FIGURE 1 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: SEGMENTATION

FIGURE 2 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: DROC ANALYSIS

FIGURE 4 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: EUROPE VS REGIONAL ANALYSIS

FIGURE 5 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: SEGMENTATION

FIGURE 10 EXECUTIVE SUMMARY

FIGURE 11 STRATEGIC DECISIONS

FIGURE 12 TWO SEGMENTS COMPRISE THE EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE (2024)

FIGURE 13 INCREASING PREVALENCE OF CANCER ACROSS GLOBE EXPECTED TO DRIVE THE EUROPE CANCER PHOTODYNAMIC THERAPY MARKET IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 14 PHOTOSENSITIZER DRUGS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CANCER PHOTODYNAMIC THERAPY MARKET IN 2025 & 2032

FIGURE 15 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET-MARKET OVERVIEW

FIGURE 16 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2024

FIGURE 17 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2024

FIGURE 18 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032

FIGURE 19 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032

FIGURE 20 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2024

FIGURE 21 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2024

FIGURE 22 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032

FIGURE 23 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032

FIGURE 24 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2024

FIGURE 25 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2024

FIGURE 26 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032

FIGURE 27 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032

FIGURE 28 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2024

FIGURE 29 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2024

FIGURE 30 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032

FIGURE 31 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032

FIGURE 32 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2024

FIGURE 33 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2024

FIGURE 34 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032

FIGURE 35 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032

FIGURE 36 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2024

FIGURE 37 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032

FIGURE 38 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032

FIGURE 39 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032

FIGURE 40 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2024

FIGURE 41 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2024

FIGURE 42 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032

FIGURE 43 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032

FIGURE 44 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024

FIGURE 45 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024

FIGURE 46 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032

FIGURE 47 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032

FIGURE 48 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: SNAPSHOT (2024)

FIGURE 49 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY SHARE 2024 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

市場は 欧州がん光線力学療法市場セグメンテーション、製品タイプ別（光感受性薬、光線力学療法機器）、がん適応症別（皮膚・皮膚腫瘍、頭頸部、食道、肺、膀胱、子宮頸部、前立腺）、治療法別（単独療法、補助療法、緩和療法、その他）、治療技術別（体外照射、腔内（内視鏡）照射、組織内（内部）照射、その他）、病期別（早期がん、後期がん）、患者属性別（高齢者、成人、小児）、エンドユーザー別（病院、皮膚科・皮膚がんクリニック、外来手術センター（ASCS）、学術研究機関、その他）、流通チャネル別（直接入札、サードパーティ販売業者、オンライン、その他） - 業界動向と2025年までの予測2032 に基づいて分類されます。
欧州がん光線力学療法市場の規模は2024年にUSD 872.14 USD Millionと推定されました。
欧州がん光線力学療法市場は2025年から2032年の予測期間にCAGR 5.8%で成長すると見込まれています。
市場で活動している主要プレーヤーはNovartis Pharma AG ,Galderma SA ,Bausch Health Companies Inc. ,Photocure ASA ,ADVANZ PHARMA Corp. ,Sun Pharmaceutical Industries Ltd.です。

関連ページを閲覧する

Banner
Testimonial
Image
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Image
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Image
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Image
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

Image
COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Image
Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Image
Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future